Previous close | 7.26 |
Open | 7.58 |
Bid | 7.52 x 100 |
Ask | 7.56 x 100 |
Day's range | 7.38 - 7.97 |
52-week range | 6.33 - 15.36 |
Volume | |
Avg. volume | 659,800 |
Market cap | 590.811M |
Beta (5Y monthly) | 2.08 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal fourth quarter and full year ended February 29, 2024. "Accolade has built a rare healthcare services business at scale with consistently strong growth rates. Whether serving consumers, employers, health plans, or government entities, the core of our value proposition is making healthcare easier to access, navigate, and consume for our members. We provide a unique blend of he
SEATTLE, April 03, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal fourth quarter 2024 financial results on Thursday, April 25, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/reg
Accolade, Inc. (Nasdaq: ACCD) today announced it has been named a winner of the Business Intelligence Group's Artificial Intelligence Excellence Awards program for its application of Natural Language Processing. This award recognizes companies leveraging AI technology to solve real-world problems. Accolade is one of the only healthcare organizations recognized this year for excellence in AI.